9 Dec 2011 Insera Therapeutics. Source: monkeybusinessimages / Getty Images. Time is of the essence when a person suffers a stroke, and Insera

About Insera: Insera Therapeutics, Inc. is an ISO 13485 certified medical device company focused on treatments for vascular diseases including stroke. CLEAR ® stands for Customizable, Luminal,

Insera Therapeutics’ CLEAR aspiration system has been used for the first time to treat a (human) patient with acute pulmonary embolism (PE). CLEAR, “cyclical luminal, evaluation, aspiration, and retrieval”, is a digital vacuum aspiration system that allows operators to employ uniform suction or cyclical suction patterns. Assignee: Insera Therapeutics, Inc. Inventors: Vallabh Janardhan, Vikram Janardhan Shape-set textile structure based mechanical thrombectomy systems Insera Therapeutics is an unclaimed page. Claim it for free to: Update listing information. Respond to reviews. Access credit score report.

Insera Therapeutics, LLC is a Sacramento, CA based medical devices company developing innovative products for treatment of various neurovascular diseases. Description Developer of medical devices designed to treat neurovascular diseases. The company's devices weaves through brain vessels and collects clots, fat deposits or debris on its way out, enabling physicians to treat neurovascular diseases through minimally invasive therapeutics. Insera Therapeutics is a Sacramento, CA based medical devices company.

The control system includes a microcontroller, an antenna configured to receive a signal, and a pump control Applicant: Insera Therapeutics, Inc. Abstract: Methods of providing embolic protection during treatment of a vessel include advancing a microcatheter in the vessel, inserting a textile structure in a collapsed state into the microcatheter, and advancing the textile structure through the microcatheter. Insera Therapeutics (Sacramento, Calif.) recently announced that it has received CE Mark approval for its Clear Aspiration System. The system is designed for blood clots and has been indicated for use in patients who have acute ischemic stroke secondary to intracranial large vessel occlusive disease, secondary to cerebral venous sinus thrombosis Insera Therapeutics’ CLEAR aspiration system has been used for the first time to treat a (human) patient with acute pulmonary embolism (PE).

Insera Therapeutics has announced that the first two ischaemic stroke patients have been treated with its flagship cyclic aspiration system, CLEAR. The company received CE mark approval for its flagship product, the CLEAR Aspiration System, in March 2019.

Stroke is the leading cause of long term disability in the United States and is the second leading cause of death worldwide with over 4.4 million deaths a year. 2019-12-03 US-based medical devices firm Insera Therapeutics has received Conformité Européenne (CE) mark approval for its CLEAR Aspiration System, a cyclical-suction stroke thrombectomy platform. Image: CT scan of brain with red area showing hemorrhagic stroke or ischemic stroke.

Insera Therapeutics doesn't have any recent trademark applications, indicating Insera Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Insera Therapeutics is a Sacramento, CA based medical devices company. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and Insera Therapeutics' CEO Vikram Janardhan gives a glimpse into future stroke devices, the innovation behind the CLEAR Aspiration System, and the Get reviews, hours, directions, coupons and more for Insera Therapeutics. Search for other Contract Manufacturing on The Real Yellow Pages®. Get reviews, hours, directions, coupons and more for Insera Therapeutics at 1560 Arcola Ave, Sacramento, CA 95835.

Private/Public: private Phone: 415-895-0945 Email: [email protected] Heated mechanical detachment for delivery of therapeutic devices: September, 2009: Jones et al. 20090209855: MEDICAL DEVICES FOR TREATING A TARGET SITE AND ASSOCIATED METHOD: August, 2009: Drilling et al. 20090198269: Device for the Removal of Thrombi From Blood Vessels: August, 2009: Hannes et al.
Cem 1901

CLEAR, “cyclical luminal, evaluation, aspiration, and retrieval”, is a digital vacuum aspiration system that allows operators to employ uniform suction or cyclical suction patterns. Get information, directions, products, services, phone numbers, and reviews on Insera Therapeutics in Sacramento, undefined Discover more Surgical and Medical Instruments and Apparatus companies in Sacramento on Manta.com Applicant: Insera Therapeutics, Inc. Abstract: Methods of providing embolic protection during treatment of a vessel include advancing a microcatheter in the vessel, inserting a textile structure in a collapsed state into the microcatheter, and advancing the textile structure through the microcatheter. Micro Therapeutics, Inc., “Mirage .008, Hydrophilic Guidewire”, 2000. Micrus Endovascular, “WATUSI guidewire, Let's Dance,” 2006.

Insera Therapeutics was a finalist at the 2018 Sacramento Innovation Awards.
Josefssons postorder ab

per kornhall barnexperimentet
rullisten
särkullbarn laglott
körning med häst utrustning
at night medical abbreviation
körkort örebro
i no longer wish to bee alive

US9463105B2 2013-03-14 2016-10-11 Covidien Lp Methods and apparatus for luminal stenting. US8679150B1 2013-03-15 2014-03-25 Insera Therapeutics,

Search for other Contract Manufacturing on The Real Yellow Pages®. Get reviews, hours, directions, coupons and more for Insera Therapeutics at 1560 Arcola Ave, Sacramento, CA 95835.

Migrationsverket svenska
omkostnadsbelopp k10

2019-12-03

Developing therapies against currently incurable cancers. Inhibiting intra-cellular protein-protein US4655746A * 1985-12-02 1987-04-07 Target Therapeutics Catheter device US9034007B2 * 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney 14 May 2020 PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The US6022363A * 1998-12-16 2000-02-08 Micro Therapeutics, Inc. Rotatable US8715315B1 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular Neutron Drugs & Pharmaceuticals Private Limited - Offering Insera-D Diclofenac Potassium & Serratiopeptidase Tablets, Neutron, Prescription at Rs 800/box in 2 May 2011 Vikram Janardhan, Founder and CEO of Insera Therapeutics; Lourdes Jimenez-Price, Senior attorney for SMUD; Becky Johnson, Director of 1 Apr 2019 Reperfusion Medicine & Life Sciences. Mechanical Thrombolysis Medicine & Life Sciences. Therapeutics Medicine & Life Sciences. [Intervju med National Science Foundation's Small Business Expert] Insera Therapeutics Insera Therapeutics. Vetenskap och affärer går inte alltid hand i hand. Vallabh Janardhan.

not be performed before reperfusion therapies such as intravenous thrombolysis Investigator), other from Insera Therapeutics, Inc (Board Member); other from

US-based medical devices firm Insera Therapeutics has received Conformité Européenne (CE) mark approval for its CLEAR Aspiration System, a cyclical-suction stroke thrombectomy platform. Image: CT scan of brain with red area showing hemorrhagic stroke or ischemic stroke. Insera Therapeutics notes their unique aspiration technology offers the ability to vary the vacuum suction pressures and intervals within the safe vacuum suction range up to -98.2 kPa (-29 inHg). reports latest medical device, biotech, diagnostic executives on the move and more Insera Therapeutics LLC Banking On The Future Of Stroke Therapy; Sacramento Startup Seeks $17.9M To Win FDA's OK For Technology Published: Jun 06, 2008 Sacramento Business Journal -- A former energy company executive in Sacramento hopes to break into the medical device market with a tiny, umbrella-like filter for stroke treatments. Insera Therapeutics Inc. edit cover image.

WHAT WE DO Stroke is the leading cause of long term disability in the United States and is the second leading cause of death worldwide with over 4.4 million deaths a year. Interested in knowing more about our innovative products and services? Contact us with your questions or comments. We want to hear from you!You can send us an email using the form on this page, or simply email us at info@inseratherapeutics.com. Insera Therapeutics General Information Description.